The radioprotective effect of a hydroalcoholic extracted material from the fruit of Aegle marmelos (AME) was studied in mice exposed to different doses of γ radiation. The optimum dose for radioprotection was determined by administering 0, 5, 10, 20, 40, or 80 mg/kg body weight of AME intraperitoneally (ip) once daily, consecutively for 5 days before exposure to 10 Gy of γ radiation. A total of 20 mg/kg of AME for 5 consecutive days before irradiation was found to afford maximum protection as evidenced by the highest number of survivors after 30 days postirradiation. Animals from all groups were monitored for 30 days postirradiation for development of symptoms of radiation sickness and mortality. Treatment of mice with AME before exposure to different doses of γ radiation reduced the severity of symptoms of radiation sickness and mortality with all exposure doses. This was accompanied by an increase in number of survivors in the AME + irradiation group when compared with the concurrent sterile physiological saline (SPS) + irradiation group. AME pretreatment protected mice against the gastrointestinal as well as bone marrow deaths, as evidenced by the greater number of survivors on day 10 or 30, respectively. LD 50/30 was found to be 8.2 Gy for the SPS + irradiation group, while it was 8.8 Gy for AME + irradiation. The dosereduction factor (DRF) was found to be 1.1 for AME + irradiation group. The acute toxicity study of AME showed that it was nontoxic up to a dose of 6 g/kg body weight, the highest drug dose that could be administered. Irradiation of animals resulted in a dose-dependent elevation in lipid peroxidation in liver, kidney, stomach, and intestine of mice. Conversely, GSH concentration declined in a dose-dependent manner. Treatment of animals with AME before irradiation caused a significant decrease in the lipid peroxidation accompanied by a significant elevation in the GSH concentration in liver, kidney, stomach, and intestine of mice determined at 31 days postirradiation. INTEGRATIVE 
Radiotherapy is an important modality for cancer cure, and it is estimated that about one half of cancer patients derive benefit from it. However, the prime importance of radiotherapy is in the treatment of locoregional growths that cannot be excised by surgery, such as those of advanced lung, head, and neck cancers. Unfortunately, high doses of radiation lead to severe esophagitis in lung cancer and acute mucositis and pharyngitis in head and neck cancer that force physicians to discontinue or lessen the treatment cycles. In such situations, an agent that can render a therapeutic differential between the cancer cell cytotoxicity and normal tissue toxicity may be of great help. Therapeutic differential may be achieved with chemical radiation sensitizers or protectors. The development of radiation protectors is important not only to enhance the effectiveness of cancer treatment but also for the study of underlying mechanisms of radiation cytotoxicity.
Chemical radiation protection has a history of about 5 decades, when the first report that the natural amino acid cysteine protected mice against radiationinduced sickness and mortality appeared in Science. 1 Since then, several compounds with varied chemical structures and pharmacological properties have been screened for their radioprotective ability in mammals. The aminothiol compounds of the cysteinecysteamine group were found to give significant radiation protection in the laboratory animals, and none of them have shown superior effect than the synthetic compound WR-2721 (S-2-(3-aminopropylamino)ethyl phosphorothioic acid). 2 However, clinical trials with WR-2721 (amifostine) have shown cumulative toxicity when administered daily before irradiation in cancer patients undergoing radiotherapy. Hypotension is the major toxicity and requires careful monitoring. The other observed side effects are dizziness, flushing, metallic taste, anxiety, urinary retention, allergic reactions, fever, hypomagnesaemia, sedation, nausea, and vomiting. With multiple doses of amifostine administration, hypocalcaemia has also been observed. [3] [4] [5] Despite extensive screening of several synthetic compounds for radioprotective activity, no single compound has emerged as a good radioprotector so far. The plants have been the companion of man since time immemorial, providing several useful drugs for the treatment of various ailments. Therefore, screening of natural dietary products represents a major avenue for the discovery of new radioprotective drugs.
Aegle marmelos (L.) Correa, commonly known as bael, is a spinous tree belonging to the plant family Rutaceae. It is grown throughout the subcontinents as well as Bangladesh, Burma, and Srilanka. The tree is also called "Shivadume," the tree of Lord Shiva. Its edible fruit, leaf, root, bark, and seed are valued in Ayurvedic medicine in India. 6 In fact, as per Charaka (1500 BC), no drug has been longer or better known or appreciated by the inhabitants of India than the bael. 7 A. marmelos has an important place in indigenous systems of medicine. With respect to clinical application, it should be noted that the unripe fruits are bitter, acrid, sour, and astringent; aid digestion and stomach irritation; and are useful in treating diarrhea, dysentery, and stomachalgia. 8 A. marmelos fruit has been reported to posses antioxidant activity. 9 Aegle leaf extract also helps in the regeneration of damaged pancreas (β cells) in diabetic rats 10 and is found to be as effective as insulin in restoring blood glucose and body weight to normal levels. 11 It has also been reported to possess cytotoxic effects on human neoplastic cell lines of different histological origins in vitro. [12] [13] Lessons from the experience with radioprotectors worldwide are that animal studies with survival as the end point are the most confirmatory, since 30-day survival after lethal whole-body irradiation clearly indicates the capacity of the drug to facilitate recovery. Regeneration of the gastrointestinal epithelium and hemopoietic progenitor cells in the bone marrow, the 2 most radiosensitive organs, is essential for sustenance of life. The common usage, wide acceptability in human beings, and diverse medicinal and antioxidative properties attributed to bael fruit stimulated us to obtain insight into the radioprotective effect of bael fruit (A marmelos) in mice exposed to various doses of whole-body γ radiation.
Materials and Methods
Animal care and handling were performed according to guidelines issued by the World Health Organization (Geneva, Switzerland) and the Indian National Science Academy (New Delhi, India). Ten-to 12-weekold male Swiss albino mice of 30 to 36 g were selected from an inbred colony maintained under controlled conditions of temperature (23°C ± 2°C), humidity (50% ± 5%), and light (14 and 10 hours of light and dark, respectively). These animals had free access to the sterile food and water. Four to 6 animals were housed in a polypropylene cage containing sterile paddy husk (procured locally) as bedding throughout the experiment. The institutional animal ethical committee of Kasturba Medical College, Manipal, approved the study.
Preparation of the Extract
A. marmelos was identified by Dr Gopal Krishna Bhat, a well-known taxonomist of this area. Fruits of the A. marmelos tree were collected locally during March through April of the year, cleaned, shade dried, powdered, and extracted. 14 Briefly, 100 g of the fruit powder was extracted with 50% ethanol at 50°C to 60°C in a Soxhlet apparatus for 72 hours. The cooled extract was concentrated to dryness in a lyophilizer. An approximate yield of 18% extract was obtained. The extract was stored in a freezer at -70°C until use. Henceforth, the extract of A. marmelos fruit will be called AME.
Acute Toxicity
The acute toxicity of AME was determined according to Prieur et al 15 and Ghosh. 16 Briefly, animals were fasted by withdrawing food and water for 18 hours. Fasted animals were divided into 8 groups of 10 each. Each group of animals was injected intraperitoneally with 1, 2, 3, 4, 5, and 6 g/kg body weight (bwt) of freshly prepared AME intraperitoneally. These animals were provided food and water immediately after the drug administration. Mortality of these animals was observed for up to 14 days post-drug treatment.
Preparation of Drugs and Mode of Administration
The drug 2-mercaptopropionylglycine (MPG) was procured from Santen Pharmaceuticals Limited (Osaka, Japan). MPG was freshly dissolved immediately before use in the sterile physiological saline (SPS) so as to give a concentration of 2 mg/mL. The pH of the solution was adjusted to 6.4 by the addition of 0.1 N sodium hydroxide before administration, while AME was prepared at a concentration of 4 mg/ mL in SPS. These animals were treated intraperitoneally with 0.01 mL/g bwt of SPS, AME, MPG unless otherwise stated, and these animals were divided into the following groups:
• SPS + irradiation: Animals of this group received SPS as described above before exposure to different doses of γ irradiation.
• MPG + irradiation group: Animals of this group were treated with 20 mg/kg bwt of MPG intraperitoneally 30 minutes before exposure to different doses of γ radiation. 17 • AME + irradiation: This group of animals was injected with AME intraperitoneally once daily for 5 consecutive days before exposure to γ radiation. 18 
Irradiation
One hour after the last administration of SPS or AME, and 30 minutes after the administration of MPG, the prostrate and immobilized animals, achieved by inserting cotton plugs in the restrainer, were whole body exposed to 60 Co γ radiation (Theratron, Atomic Energy Agency, Canada) in a specially designed wellventilated acrylic box. A batch of 10 animals was irradiated each time at a dose rate of 1.66 Gy/min at a source-to-animal distance (midpoint) of 70 cm. Animals were grouped as described above for the experiments listed below.
Selection of Optimum Dose
A separate experiment was carried out to determine the optimum dose of AME, in which animals were divided into 3 groups as described above. The former group received 0.01 mL/g bwt of SPS, while the latter group was treated with 5, 10, 20, 40, or 80 mg/kg bwt of AME intraperitoneally once daily for 5 consecutive days. One hour after the last administration on the fifth day, animals of both groups were exposed to 10 Gy γ radiation. 13 This allowed the preliminary screening of optimum drug dose of AME. A total of 20 mg/kg bwt was found to be the best radioprotective dose; therefore, further studies were performed using this dose of AME.
Effect of Route of Administration
An attempt was also made to select the most effective route of administration of AME for radioprotection, in which animals were administered 20 mg/kg bwt of AME orally or intraperitoneally once daily for 5 consecutive days before exposure to 10 Gy γ radiation.
Radioprotective Effect
A separate experiment was carried out to ascertain the radioprotective ability of AME, in which animals were divided into 3 groups as described above. One hour after the last administration of SPS or AME, and 30 minutes after the administration of MPG, animals were exposed to 7, 8, 9, 10, or 11 Gy of γ radiation.
Animals in all experiments were monitored daily for the development of symptoms of radiation sickness and mortality for up to 30 days postirradiation. The dose-reduction factor (DRF) was calculated by the method of Miller and Tainter 19 as follows:
LD of theAME irradiation group LD of SPS irradia 50 50 tion group .
Biochemical Determinations
Biochemical determinations were carried out in survivors of both AME + irradiation and SPS + irradiation groups on day 31 postexposure. These animals were killed by cervical dislocation, and their livers were perfused transcardially with ice-cold saline. The whole liver, stomach, intestine, and kidney were removed, blot dried, and weighed, and a 10% homogenate was prepared with an ice-cold 0.2-M sodium phosphate buffer pH 8.0 using a homogenizer (Yamato LH-21, Tokyo, Japan).
Protein
Total proteins were determined by the method of Lowry et al 20 using bovine serum albumin as a standard.
Glutathione (GSH)
GSH contents were measured using the method of Moron et al. 21 Briefly, proteins were precipitated with 25% TCA and centrifuged, and supernatant was collected. The supernatant was mixed with 0.2 M sodium phosphate buffer pH 8.0 and 0.06 mM DTNB and incubated for 10 minutes at room temperature. The absorbance of the samples was read against the blank at 412 nm in an ultraviolet (UV)-visible spectrophotometer (Shimadzu UV-260, Shimadzu Corp, Tokyo, Japan), and the GSH concentration was calculated from a standard curve.
Lipid Peroxidation (LPx)
LPx was measured by the method of Beuege and Aust. 22 Briefly, the tissue homogenate was mixed with TCA-TBA-HCl, and the resultant mixture was heated for 15 minutes in a boiling water bath. After centrifugation, the absorbance was recorded at 535 nm using a UV-visible spectrophotometer. Lipid peroxidation is expressed as malonaldehyde (MDA) in nmol/ mg protein.
Analysis of Data
A statistically significant difference between treatments was determined using the Z test 23 for survival studies, while the Student t test was used for biochemical determinations. All data are expressed as mean ± SEM.
Results

Acute Toxicity
The administration of 1 to 6 g/kg bwt of AME did not induce a single death during the observation period.
However, a further increase in the drug dose was not possible due to experimental constraints. Therefore, AME was considered nontoxic up to a dose of 6 g/kg bwt.
Selection of Optimum Dose
The optimum dose of AME for radiation protection was selected by injecting mice with 0, 5, 10, 20, 40, or 80 mg/kg bwt AME before whole-body exposure to 10 Gy γ radiation. These animals were monitored daily for 30 days for the development of symptoms of radiation sickness and mortality. Daily administration of different doses of AME for 5 consecutive days did not cause drug-induced mortality. Exposure of the SPS + irradiation group to 10 Gy induced symptoms of severe radiation sickness, reduction in food and water intake, irritability, lacrimation, lethargy, diarrhea, body weight loss, emaciation, facial edema, epilation, and so on. The first mortality in the SPS + irradiation group was observed at day 3, and all of the irradiated animals died by day 16 postirradiation. The pretreatment of mice with various doses of AME either delayed or reduced the severity of symptoms of radiation sickness. The onset of radiation-induced mortality was also delayed in the AME + irradiation groups when compared with the SPS + irradiation group. The longest delay was observed for 20 mg/kg AME-treated group, in which the first death was observed on day 5 postirradiation ( Figure 1) .
A majority of the SPS + 10 Gy irradiation group animals (75%) died within 10 days after irradiation. However, administration of MPG resulted in 42% mortality by day 10, and survival was 2.3-fold greater than in the SPS + 10 Gy irradiation group. Treatment of mice with various doses of AME had an ameliorating effect on the gastrointestinal tract as evidenced by an increase in the 10-day survival of mice, in which an increase of 1.3-, 1.8-, 2-, 1.3-, or 1.7-fold was observed for the 5, 10, 20, 40, or 80 mg/kg AME-treated groups, respectively. The lowest mortality of 50% was observed for animals treated with 20 or 40 mg/kg before irradiation. Other doses of AME also reduced mortality, in comparison with SPS + 10 Gy irradiation; however, a significant elevation in the 10-day survival was observed only for 20 and 40 mg/kg AME (P < .001) treatments ( Figure 2 ). Analysis of 30-day survival revealed an AME dosedependent increase in survival of irradiated animals with doses increasing up to 20 mg/kg, in which the highest survival of 29% was observed as compared to the SPS + irradiation group, in which no survivors were reported ( Figure 1 ). An increase in drug dose to 40 or 80 mg resulted in 17% or 8% reduction, respectively, in survival when compared with the 20 mg/kg AME + irradiation group (Figure 2 ). The lower dose of 10 mg/kg AME also increased the survival by 8% when compared with the SPS + irradiation group, in which no survivors were observed. There were no survivors in the lower dose of 5 mg/kg AME. A significant elevation in survival was observed only in animals that received 20 or 40 mg/kg AME before exposure to 10 Gy. Since maximum survival was observed for 20 mg/ kg AME, it was considered to be an optimal dose for radioprotection, and further studies were performed using this dose ( Figure 2 ).
Effect of Route of Administration
Administration of 20 mg/kg AME once daily consecutively for 5 days by the intraperitoneal or oral route before irradiation to 10 Gy mice had an ameliorating effect on the gastrointestinal tract, as evidenced by an increase in the 10-day survival of mice, which was 2and 1.3-fold greater, respectively, in the AME + irradiation groups when compared with SPS + irradiation group. The first death was observed on day 3, and only 25% of the SPS + 10 Gy irradiation group survived up to day 10. The first death in the mice administered AME intraperitoneally was observed on day 5, where 50% of these animals survived on day 10, while the first death in the orally treated animals was observed on day 4 and 33% survived up to day 10 postirradiation ( Figure 3 ). Intraperitoneal administration of AME caused a 1.5-fold increase in the survival when compared with oral administration (Figure 4 ). The analysis of 30-day survival revealed that the radioprotective activity was better when the drug was administered through the intraperitoneal rather than the oral route, as 29% of the intraperitoneally treated animals survived up to day 30 postirradiation, whereas no survivors were observed in the group of mice receiving AME orally (Figure 4 ). Despite this, oral treatment prolonged life span and reduced radiation sickness as the last animal of this group died on day 16 postirradiation (Figure 3 ).
Radioprotective Effect
The radioprotective action of AME was evaluated using an optimal dose of 20 mg/kg by intraperitoneal administration for 5 consecutive days before exposure to 7, 8, 9, 10, or 11 Gy of γ radiation. The irradiation of animals using different doses resulted in the development of symptoms of radiation sickness within 2 to 4 days after exposure, depending on the irradiation dose for the SPS + irradiation group. Exposure of mice to higher radiation doses resulted in an early onset of symptoms of radiation sickness and mortality. Facial edema was also observed in a few animals between 1 and 2 weeks after exposure to 9 or 10 Gy. The severity of these symptoms increased with the increase in radiation dose. With increasing dose of radiation, the survival declined in a dose-dependent manner until a nadir in survival was reached at 10 Gy, at which point no survivors were reported beyond 16 days postirradiation. With the increase in radiation dose, the onset of mortality was also advanced ( Figure 5 ).
Pretreatment of mice with 20 mg/kg AME delayed or reduced the severity of radiation sickness and also delayed the onset of radiation-induced mortality when compared with the concurrent SPS + irradiation group ( Figure 5 ). This delay in the onset of death was 4 to 5 days for the AME + irradiation group when compared with the SPS + irradiation groups. Gastrointestinal deaths were fewer for the AME + irradiation group when compared to the SPS + irradiation group for all radiation doses ( Figures 5, 6a ). Pretreatment of mice with AME reduced the 10-day mortality by 1.4-and 2fold for 9 (P < .05) and 10 Gy (P < .001) irradiation, respectively. Administration of AME resulted in 46% survivals with the 11 Gy dose, while no animals survived beyond day 9 postirradiation in the concurrent control group on day 10 (Figure 5d, 5e ). Pretreatment of mice with AME reduced the 30-day mortality by 1.2and 2.6-fold for 8 and 9 Gy irradiation, respectively. The administration of AME before exposure to 10 Gy radiation resulted in 41.6% survival, while no survivors were observed in the concurrent control group. Survival is plotted as log values versus a linear irradiation dose scale, and the LD 50/30 was found to be 8.2 Gy for the SPS-treated group (Figure 6b ), while it was 8.8 Gy for the AME + irradiation group. The DRF was found to be 1.1. 
Radioprotective Effect of Aegle marmelos
GSH
Results are expressed as GSH µmol/g tissue ( Figure  7 ). Administration of AME alone before sham irradiation did not alter tissue glutathione contents significantly. Exposure of animals to different doses of γ radiation resulted in a significant and dose-dependent decline in GSH contents in the liver, intestine, kidney, and stomach of mice in the SPS + irradiation group. AME pretreatment restored normal GSH levels in all organs in animals exposed to 6 or 7 Gy in the AME + irradiation group (Figure 7) .
LPx
LPx is expressed as nmol MDA/mg protein ( Figure  8 ). LPx remained unaltered in the SPS + sham irradiation group at all postexposure time periods. Administration of AME before sham irradiation did not alter the lipid peroxidation in all the tissues (Figure 8 ). Exposure of animals to different doses of radiation in-creased lipid peroxidation in a dose-dependent manner for both the SPS + irradiation and AME + irradiation groups, and peak levels were observed after 10 Gy irradiation. AME pretreatment significantly reduced LPx induction in the AME + irradiation groups, thereby protecting liver, intestine, kidney, and stomach tissues against radiation-induced lipid peroxidation at all exposure doses studied. Despite the reduction in LPx by AME, LPx levels did not return to normal by day 31 postirradiation (Figure 8 ).
Discussion
There is continued interest and need for the identification and development of effective nontoxic radioprotectors that could potentially protect humans against the deleterious effects of radiation in occupational as well as in therapeutic settings, especially during the treatment of cancer. However, most of the radioprotectors studied so far have been reported to exert severe toxic effects at their optimal radioprotective doses, thus inhibiting their applicability in clinics. 24 Dietary ingredients may be very useful if they are found to protect against the deleterious effects of ionizing radiation, as they will be widely acceptable, would not put an extra foreign substance into the body, and can be safely manipulated without toxic manifestations. Bael fruits are consumed in India as such or in the form of sherbet and also possess several potentially useful medicinal properties. 25 In this study, for the first time we have attempted to evaluate the radioprotective effect of A. marmelos in mice.
Whole-body irradiation primarily affects rapidly proliferating germinal epithelium, gastrointestinal epithelium, bone marrow, and spleen progenitor cells. While the germinal epithelium does not have a life-supporting function for the exposed individual, the gastrointestinal epithelium and the bone marrow and spleen progenitor cells are crucial for the sustenance of life, and any damage to these cells will impair normal physiological host defense processes drastically, causing an adverse impact on survival. In mice, death within 10 days postirradiation is due to gastrointestinal epithelial damage along with immunocompromise. [26] [27] [28] Bone marrow and spleen stem cells are more sensitive to radiation damage than the intestinal crypt, but the peripheral blood cells have a longer transit time than the intestinal cells, and hence the gastrointestinal syndrome appears earlier than the bone marrow syndrome. Death due to irradiation occurring between 11 to 30 days postirradiation is due to both intestinal and hemopoietic damage inflicted by radiation. 18, 26, 28 Our study indicates that bael provided the highest protection against radiation-induced mortality at 20 mg/kg intraperitoneally when given once daily for 5 consecutive days. A decline in the effect has been observed earlier for various other extracts. 18, 28, 29 Earlier studies of radioprotection have shown that an agent being tested for radioprotective action acts only at a particular dose, above which it may not be protective and in some cases can even be toxic. 17, 18, 27, 30, 31 A similar action cannot be ruled out in the present study, in which optimal protection by AME at 20 mg/kg was observed while higher doses resulted in a decline in the protective action of AME. The same schedule when followed for equimolar oral doses did not afford significant protection when compared to the intraperitoneal route, and none of the animals survived beyond 17 days postirradiation. This may be due to faster absorption of the AME through the intraperitoneal route, while administration through the oral route may require higher doses of AME to get the same degree of protection. A similar observation has also been reported for Ocimum sanctum, ginger and abana, a polyherbal formulation. 18, 29, 32 Plants such as O. sanctum, Moringa oleifera, Mentha arvensis, and Syzygium cumini have been reported to protect mice against radiation-induced sickness and mortality. 18, [33] [34] [35] Similarly, other plants such as Spirulina platensis, Allium sativum, Withania somnifera, O. sanctum, Chlorella vulgaris, Phyllanthus niruri, Panax ginseng, and Ginkgo biloba have also been reported to protect mice against radiation-induced tissue damage. [36] [37] [38] [39] [40] [41] AME pretreatment protected mice against radiation-induced death due to gastrointestinal as well as bone marrow syndromes, as evident by a higher number of survivors observed following AME treatment. Similar effects were observed earlier with various radioprotective substances. 18, 27, 28, 31, 33 Reduction in gastrointestinal death may be due to protection of intestinal epithelium, which would have allowed proper absorption of nutrients when compared with the SPS + irradiation and MPG + irradiation, the positive control used in this study. Bael has been reported to possess antiulcer activity. 42 Cineol and eugenol, 2 constituents of AME, have been reported to prevent ethanol-induced gastric injury in rats. 43, 44 Bael leaf oil has also been reported to exhibit a broad spectrum of antibacterial and antifungal activity. 45 The hemopoietic syndrome is induced with low doses of irradiation and is manifested by hemopoietic stem cell depletion and ultimately by the depletion of mature hemopoietic and immune cells. Pretreatment of mice with AME significantly reduced bone marrow syndrome deaths in the AME + irradiation group, especially with doses of 20 or 40 mg/kg, with which a significant elevation in survival was observed. This increase in 30-day survival may be due to protection afforded by AME to the stem cell compartments of bone marrow and spleen, which continued to supply the requisite number of cells in survivors. AME treat-ment increased LD 50 up to 8.8 Gy, raising it by 0.6 Gy over the LD 50 of SPS + irradiation group, and the DRF was 1.1. A similar effect was observed earlier for O. sanctum, ginger, M. arvensis, and S. cumini. 18, 28, 31, 33 Plants are complex mixtures of compounds, and no single compound may provide the observed activity. Plant extracts can be characterized as polyvalent formulations and interpreted as additive or, in some cases, potentiating. 46 The exact mechanism of action of AME is not known. Ionizing radiation induces lipid peroxidation resulting in DNA damage and cell death. [47] [48] [49] Therefore, any agent that can protect against such damage can provide protection against radiation damage. The radioprotective action of AME cannot be due to a single mechanism but to multiple mechanisms. AME may have scavenged free radicals produced by radiation, reducing the radiationinduced damage and increasing mouse survival. This contention is supported by earlier reports, in which AME fruit and leaf extracts have been reported to scavenge free radicals in vitro. 9, 50 The significant elevation in GSH level and reduction in lipid peroxidation at all exposure doses by AME may be responsible for radioprotection against radiation-induced mortality in the present study. Bael fruit extract has been reported to increase GSH in blood and liver of mice and to increase the activities of other antioxidant enzymes such as superoxide dismutase, catalase, and glutathione peroxidase, as well as to reduce lipid peroxidation. 9 Bael has been reported to contain aegeline, aegelenine, marmelosine, marmelin, o-methyl hayordinol, alloimperratorin methyl ester, o-isopentanyl hayordinol, linoleic acid, cineole, p-cymene, citronella, citral, cuminaldehyde, Dlimonene, eugenol, tannins, phlobatannins, flavon-3ols, leucoanthocyanins, anthocyanins, and flavonoid glycosides. 51 Most of these compounds have been reported to possess antioxidative and free radical scavenging activities. 52, 53 Furthermore, eugenol administration has been reported to increase GSH levels in the intestine of rats. 53 Bael leaf has also been reported to increase blood glutathione contents and reduce lipid peroxidation by maintaining activities of the antioxidant enzymes: superoxide dismutase, catalase, and glutathione peroxidase in mice. 54 All these phenomena may have contributed to the observed radioprotection by AME in the present study.
The development of radioprotectors is dependent on several factors. First, preclinical studies must show that compounds under development are in vivo radioprotectors. Second, the compounds must be associated with acceptable toxicity in preclinical studies at the doses that are required for radioprotection. Third, some therapeutic gain must be associated with the administration of the compound by giving differ-ential protection to normal tissues when compared to tumor. In lieu of these, our study is the first step toward the development of a radioprotective agent AME that satisfies the first 2 criteria. Bael fruit provided protection against radiation-induced sickness and mortality in vivo, and the optimum protective dose of 20 mg/kg (nontoxic up to 6 g/kg) was devoid of any toxic side effects. AME does not affect normal lymphocytes at doses that have been found to be cytotoxic to neoplastic cell lines, for example, leukemia K562, T-lymphoid Jurkat, B-lymphoid Raji, erythroleukemic HEL, melanoma Colo38, and breast cancer MCF7 and MDA-MB-231 cell lines in vitro, 12, 13, 50 and also in mice bearing Ehrlich ascites carcinoma. 55 This property may give a therapeutic gain in the clinical situation as the AME may selectively kill the neoplastic cells while sparing the normal cells. This could be made possible by protection of normal cells by AME, with no such effect on the tumor tissue. The mechanism by which AME may protect normal versus tumor tissue from the toxicity of radiotherapy is based on physiological differences between the 2 tissue types, resulting in the differential uptake of AME in normal versus tumor tissue. This may cause varied drug distribution into normal and tumor tissues. AME levels may reach to higher levels in normal tissues than cancerous tissue because of relatively poorer tumor vascularity. 56 Specific radioprotection of normal tissue represents a promising approach to improve radiotherapy. The ultimate feature of a normal tissue-selective radioprotector is that tumor tissue is excluded from protection. The possibility of tumor protection may not be ruled out completely, and there is a need for emphasis on further research in this area for efficient cancer therapy. Additional studies are planned to explore whether AME is selectively cytotoxic to neoplastic cells and also to observe for the differential radiation protection with suitable in vitro and in vivo models.
